AAX Biotech’s two platforms, Seqitope and Opti-mAb, address key challenges in antibody engineering and therapeutic design, supporting the creation of more effective and developable medicines. 

Daiichi Sankyo through its Daiichi Sankyo Research Institute in Munich will evaluate the capabilities of Opti-mAb and explore opportunities for broader collaboration aimed at addressing critical unmet medical needs. AAX Biotech’s Opti-mAb platform stabilizes the inherently unstable single-chain variable fragment (scFv) antibodies . 

“For AAX Biotech, collaborating with a company with the scale and reputation of Daiichi Sankyo represents a tremendous validation of our innovative approach,” says Maria Lisa Knudsen, CEO of AAX Biotech. “This provides us with the opportunity to showcase the power of Opti-mAb in collaboration with a truly global leader in pharmaceutical innovation. We are excited to work closely with the world-class scientific teams at Daiichi Sankyo.”